Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts

This study reports characteristics and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) receiving nivolumab in second-line or later (2L+) in France and Germany between 2015 and 2020. Patients with aNSCLC (stage IIIB–C/IV) receiving nivolumab in 2L+ were in...

Full description

Bibliographic Details
Main Authors: Christos Chouaid, Michael Thomas, Didier Debieuvre, Isabelle Durand-Zaleski, Stefan Zacharias, Lise Bosquet, Annika Groth, Annette Fleitz, Alan Calleja, Sonya Patel, Laure Lacoin, Melinda J. Daumont, John R. Penrod, Robert Carroll, Daniela Waldenberger, François-Emery Cotté, Clarisse Audigier-Valette, Frank Griesinger
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
nivolumab
non-small cell lung cancer
immune checkpoint inhibitor
clinical practice
I-O Optimise
real-world evidence
Online Access:https://www.mdpi.com/2072-6694/14/24/6148

Internet

https://www.mdpi.com/2072-6694/14/24/6148

Similar Items